China accused of dumping key drug in India

17 June 2020

India is set to impose anti-dumping duty on Chinese antibacterial drug ciprofloxacin hydrochloride in order to guard its domestic industry from cheap imports from the Asian neighbor.

The Directorate General of Trade Remedies (DGTR) has already recommended that provisional anti-dumping duties be imposed on ciprofloxacin imports from China. The DGTR has recommended anti-dumping duty of $0.94 per kg to $3.29 per kg.

China has been dumping ciprofloxacin below cost in the Indian market and hurting the domestic pharmaceutical industry. China accounts for about 98% of the total Indian imports of the medicine which is used to treat bacterial infections, including skin, bone, respiratory and urinary tract infections, and certain types of diarrhea.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK